Core Insights - Athira Pharma has completed a Phase 1 clinical study of ATH-1105, a potential treatment for amyotrophic lateral sclerosis (ALS), and is on track to begin dosing ALS patients in 2025 [1][3][8] Clinical Development & Pipeline Programs - ATH-1105 is a novel, orally available small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is aimed at treating neurodegenerative diseases including ALS, Alzheimer's disease, and Parkinson's disease [5][4] - The Phase 1 clinical trial of ATH-1105 involved 80 healthy volunteers and demonstrated a favorable safety profile, supporting its continued development [8] - Preclinical evidence indicates that ATH-1105 has shown significant improvements in motor and nerve function, as well as biomarkers of inflammation and neurodegeneration [8] Financial Results - As of December 31, 2024, Athira reported cash, cash equivalents, and investments of $51.3 million, a decrease from $147.4 million in 2023 [13] - Research and Development (R&D) expenses for 2024 were $70.7 million, down from $93.8 million in 2023, primarily due to reduced costs associated with the fosgonimeton program [13] - The net loss for the year ended December 31, 2024, was $96.9 million, or $2.52 per share, compared to a net loss of $117.7 million, or $3.09 per share, for the previous year [13][17] Strategic Alternatives - Following the topline results of the LIFT-AD trial, Athira is exploring strategic alternatives to maximize stockholder value and has engaged Cantor Fitzgerald & Co. as an advisor [9] - The company has paused further development of fosgonimeton while continuing to advance ATH-1105 and explore potential partnerships [9]